352 related articles for article (PubMed ID: 16132345)
1. Human multidrug resistance associated protein 4 confers resistance to camptothecins.
Tian Q; Zhang J; Tan TM; Chan E; Duan W; Chan SY; Boelsterli UA; Ho PC; Yang H; Bian JS; Huang M; Zhu YZ; Xiong W; Li X; Zhou S
Pharm Res; 2005 Nov; 22(11):1837-53. PubMed ID: 16132345
[TBL] [Abstract][Full Text] [Related]
2. Topotecan is a substrate for multidrug resistance associated protein 4.
Tian Q; Zhang J; Chan SY; Tan TM; Duan W; Huang M; Zhu YZ; Chan E; Yu Q; Nie YQ; Ho PC; Li Q; Ng KY; Yang HY; Wei H; Bian JS; Zhou SF
Curr Drug Metab; 2006 Jan; 7(1):105-18. PubMed ID: 16454695
[TBL] [Abstract][Full Text] [Related]
3. ATP-Dependent efflux of CPT-11 and SN-38 by the multidrug resistance protein (MRP) and its inhibition by PAK-104P.
Chen ZS; Furukawa T; Sumizawa T; Ono K; Ueda K; Seto K; Akiyama SI
Mol Pharmacol; 1999 May; 55(5):921-8. PubMed ID: 10220571
[TBL] [Abstract][Full Text] [Related]
4. Sensitivity to anticancer agents and resistance mechanisms in clear cell carcinoma of the ovary.
Itamochi H; Kigawa J; Sultana H; Iba T; Akeshima R; Kamazawa S; Kanamori Y; Terakawa N
Jpn J Cancer Res; 2002 Jun; 93(6):723-8. PubMed ID: 12079522
[TBL] [Abstract][Full Text] [Related]
5. Expression of multidrug transporter MRP4/ABCC4 is a marker of poor prognosis in neuroblastoma and confers resistance to irinotecan in vitro.
Norris MD; Smith J; Tanabe K; Tobin P; Flemming C; Scheffer GL; Wielinga P; Cohn SL; London WB; Marshall GM; Allen JD; Haber M
Mol Cancer Ther; 2005 Apr; 4(4):547-53. PubMed ID: 15827327
[TBL] [Abstract][Full Text] [Related]
6. Effect of P-glycoprotein modulator, cyclosporin A, on the gastrointestinal excretion of irinotecan and its metabolite SN-38 in rats.
Arimori K; Kuroki N; Hidaka M; Iwakiri T; Yamsaki K; Okumura M; Ono H; Takamura N; Kikuchi M; Nakano M
Pharm Res; 2003 Jun; 20(6):910-7. PubMed ID: 12817897
[TBL] [Abstract][Full Text] [Related]
7. Active efflux of CPT-11 and its metabolites in human KB-derived cell lines.
Chu XY; Suzuki H; Ueda K; Kato Y; Akiyama S; Sugiyama Y
J Pharmacol Exp Ther; 1999 Feb; 288(2):735-41. PubMed ID: 9918583
[TBL] [Abstract][Full Text] [Related]
8. Involvement of up-regulation of hepatic breast cancer resistance protein in decreased plasma concentration of 7-ethyl-10-hydroxycamptothecin (SN-38) by coadministration of S-1 in rats.
Yokoo K; Hamada A; Watanabe H; Matsuzaki T; Imai T; Fujimoto H; Masa K; Imai T; Saito H
Drug Metab Dispos; 2007 Sep; 35(9):1511-7. PubMed ID: 17537871
[TBL] [Abstract][Full Text] [Related]
9. Growth inhibitory effect of a new camptothecin analog, DX-8951f, on various drug-resistant sublines including BCRP-mediated camptothecin derivative-resistant variants derived from the human lung cancer cell line PC-6.
Ishii M; Iwahana M; Mitsui I; Minami M; Imagawa S; Tohgo A; Ejima A
Anticancer Drugs; 2000 Jun; 11(5):353-62. PubMed ID: 10912951
[TBL] [Abstract][Full Text] [Related]
10. Experimental antitumor activity and pharmacokinetics of the camptothecin analog irinotecan (CPT-11) in mice.
Bissery MC; Vrignaud P; Lavelle F; Chabot GG
Anticancer Drugs; 1996 Jun; 7(4):437-60. PubMed ID: 8826613
[TBL] [Abstract][Full Text] [Related]
11. Differential effects of the breast cancer resistance protein on the cellular accumulation and cytotoxicity of 9-aminocamptothecin and 9-nitrocamptothecin.
Rajendra R; Gounder MK; Saleem A; Schellens JH; Ross DD; Bates SE; Sinko P; Rubin EH
Cancer Res; 2003 Jun; 63(12):3228-33. PubMed ID: 12810652
[TBL] [Abstract][Full Text] [Related]
12. Transcriptional targeting of human liver carboxylesterase (hCE1m6) and simultaneous expression of anti-BCRP shRNA enhances sensitivity of breast cancer cells to CPT-11.
Mishra MN; Vangara KK; Palakurthi S
Anticancer Res; 2014 Nov; 34(11):6345-51. PubMed ID: 25368234
[TBL] [Abstract][Full Text] [Related]
13. Active transepithelial transport of irinotecan (CPT-11) and its metabolites by human intestinal Caco-2 cells.
Yamamoto W; Verweij J; de Bruijn P; de Jonge MJ; Takano H; Nishiyama M; Kurihara M; Sparreboom A
Anticancer Drugs; 2001 Jun; 12(5):419-32. PubMed ID: 11395570
[TBL] [Abstract][Full Text] [Related]
14. Analysis of the MRP4 drug resistance profile in transfected NIH3T3 cells.
Lee K; Klein-Szanto AJ; Kruh GD
J Natl Cancer Inst; 2000 Dec; 92(23):1934-40. PubMed ID: 11106685
[TBL] [Abstract][Full Text] [Related]
15. CPT-11 sensitivity in relation to the expression of P170-glycoprotein and multidrug resistance-associated protein.
Jansen WJ; Hulscher TM; van Ark-Otte J; Giaccone G; Pinedo HM; Boven E
Br J Cancer; 1998; 77(3):359-65. PubMed ID: 9472629
[TBL] [Abstract][Full Text] [Related]
16. Camptothecin analogues with enhanced antitumor activity at acidic pH.
Adams DJ; Dewhirst MW; Flowers JL; Gamcsik MP; Colvin OM; Manikumar G; Wani MC; Wall ME
Cancer Chemother Pharmacol; 2000; 46(4):263-71. PubMed ID: 11052623
[TBL] [Abstract][Full Text] [Related]
17. Reduced cellular accumulation of topotecan: a novel mechanism of resistance in a human ovarian cancer cell line.
Ma J; Maliepaard M; Nooter K; Loos WJ; Kolker HJ; Verweij J; Stoter G; Schellens JH
Br J Cancer; 1998 May; 77(10):1645-52. PubMed ID: 9635842
[TBL] [Abstract][Full Text] [Related]
18. An enhanced active efflux of CPT-11 and SN-38 in cisplatin-resistant human KB carcinoma cells.
Chen ZS; Sumizawa T; Furukawa T; Ono K; Tani A; Komatsu M; Akiyama S
Cancer Lett; 1999 Apr; 138(1-2):13-22. PubMed ID: 10378768
[TBL] [Abstract][Full Text] [Related]
19. Determinants of CPT-11 and SN-38 activities in human lung cancer cells.
van Ark-Otte J; Kedde MA; van der Vijgh WJ; Dingemans AM; Jansen WJ; Pinedo HM; Boven E; Giaccone G
Br J Cancer; 1998 Jun; 77(12):2171-6. PubMed ID: 9649129
[TBL] [Abstract][Full Text] [Related]
20. Paclitaxel and SN-38 overcome cisplatin resistance of ovarian cancer cell lines by down-regulating the influx and efflux system of cisplatin.
Komuro Y; Udagawa Y; Susumu N; Aoki D; Kubota T; Nozawa S
Jpn J Cancer Res; 2001 Nov; 92(11):1242-50. PubMed ID: 11714450
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
